Bioavailability of oxycodone by mouth in coronary artery bypass surgery patients - a randomized trial.

Antti ValtolaJames Denzil MorsePawel FlorkiewiczHeidi HautajärviPasi LahtinenTadeusz MusialowiczBrian Joseph AndersonVeli-Pekka RantaHannu Kokki

Published in: Journal of drug assessment (2020)

Bioavailability of oxycodone by mouth was similar after CAB surgery via CECC or having OPCAB. Data indicate that POD2 is an appropriate time to start oxycodone administration by mouth after CAB surgery.

Keyphrases

coronary artery bypass
percutaneous coronary intervention
minimally invasive
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
surgical site infection
coronary artery disease
acute coronary syndrome
electronic health record
big data
atrial fibrillation
artificial intelligence